HER2 Biomarker Testing in Breast and Gastrointestinal Cancers: The Role of the Pathologist

home / scientific-interchange-and-workshop / her2-biomarker-testing-in-breast-and-gastrointestinal-cancers-the-role-of-the-pathologist

Funding from Daiichi Sankyo; Content Developed Independently by OncLive.

Rachel E. Factor, MD, MS

EP. 1: Dr. Factor on the Lack of Standardization in Biomarker Testing in Breast and GI Cancers

January 25th 2022

Rachel E. Factor, MD, MS, discusses the lack of standardization with biomarker testing in breast and gastrointestinal cancers.

Rondell P. Graham, MBBS

EP. 2: Dr. Graham on the Role of the Pathologist in Biomarker Testing in Breast and GI Cancers

January 25th 2022

Rondell P. Graham, MBBS, discusses the role of the pathologist in biomarker testing for patients with breast and gastrointestinal cancers.

Aatur D. Singhi, MD, PhD

EP. 3: Dr. Singhi on the Importance of Multidisciplinary Care With Pathologists in Cancer

January 25th 2022

Aatur D. Singhi, MD, PhD, discusses the importance of facilitating multidisciplinary conversations that include pathologists in cancer care.

HER2 Biomarker Testing in Breast and Gastrointestinal Cancers: The Role of the Pathologist

EP. 4: HER2 Biomarker Testing in Breast and Gastrointestinal Cancers: The Role of the Pathologist

February 25th 2022

This publication provides a summary of key stakeholder insights on methodological limitations and analytical factors to consider pertaining to biomarker testing for HER2+ across cancer types, with particular emphasis on the role of the pathologist in the multidisciplinary management of cancer.